Core Insights - The stock of Yiming Oncology-B (01541) rose over 5%, currently up 5.22% at HKD 11.47, with a trading volume of HKD 40.4765 million [1] Group 1: Nobel Prize Announcement - Three scientists, including Mary E. Blenko, were awarded the 2025 Nobel Prize in Physiology or Medicine for their research on peripheral immune tolerance mechanisms [1] - This innovative research identified the immune system's inhibitory switch, offering transformative therapies for millions suffering from autoimmune diseases and cancer [1] - Regulatory T cells (Treg cells) maintain immune tolerance through the Foxp3 transcription factor, with their dysfunction closely linked to autoimmune diseases and cancer [1] Group 2: Development of Tazlestobart - Yiming Oncology is actively advancing the clinical development of Tazlestobart (IMM27M), a next-generation CTLA-4 antibody [2] - Tazlestobart works by eliminating Treg cells in the tumor microenvironment to exert its anti-tumor effects [2] - The drug enhances ADCC activity through genetic engineering, targeting specific molecules on Treg cells to modulate their function or quantity, thereby boosting immune responses [2]

Core Viewpoint - The stock of Iminconco-B (01541) has risen over 5% due to increased attention on Treg cell therapy and the active clinical development of Tazlestobart monoclonal antibody [1][2] Group 1: Company Developments - Iminconco-B's stock price increased by 5.22%, reaching 11.47 HKD, with a trading volume of 40.47 million HKD [1] - The company is actively advancing the clinical development of Tazlestobart (IMM27M), a next-generation CTLA-4 antibody [2] Group 2: Scientific Recognition - Three scientists, including Mary E. Blenko, were awarded the 2025 Nobel Prize in Physiology or Medicine for their research on peripheral immune tolerance mechanisms, which has implications for autoimmune diseases and cancer therapies [1] - The discovery of regulatory T cells (Treg cells) and their mechanisms has provided a theoretical foundation for developing new immunomodulatory drugs [1] Group 3: Product Mechanism - Tazlestobart (IMM27M) is designed to eliminate Treg cells in the tumor microenvironment, enhancing anti-tumor efficacy [2] - The drug utilizes genetic engineering to enhance ADCC activity and targets specific molecules on Treg cells, particularly CTLA-4, to modulate their function or quantity [2]

Core Viewpoint - The announcement of the Nobel Prize in Physiology or Medicine is expected to stimulate the development of Treg cell therapy and innovative drug research, benefiting companies like HAPO Pharmaceuticals [1] Company Summary - HAPO Pharmaceuticals-B (02142) saw its stock price rise over 8% in early trading, currently up 6.3% at HKD 16.36, with a trading volume of HKD 58.26 million [1] - The company is developing a next-generation antibody HBM4003 targeting the CTLA-4 pathway, which has shown excellent safety characteristics in clinical studies and demonstrated clear efficacy signals in multiple tumor types, including colon cancer, liver cancer, and neuroendocrine tumors [1] - HAPO's antibody HBM1022, targeting the CCR8 pathway, is considered a highly promising candidate in its pipeline, potentially leading to breakthroughs in tumor immunotherapy [1]